6hqu
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Humanised RadA mutant HumRadA22 in complex with a recombined BRC repeat 8-2== | |
| + | <StructureSection load='6hqu' size='340' side='right'caption='[[6hqu]], [[Resolution|resolution]] 1.97Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6hqu]] is a 15 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Pyrococcus_furiosus_DSM_3638 Pyrococcus furiosus DSM 3638]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6HQU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6HQU FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.97Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6hqu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6hqu OCA], [https://pdbe.org/6hqu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6hqu RCSB], [https://www.ebi.ac.uk/pdbsum/6hqu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6hqu ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [https://www.uniprot.org/uniprot/BRCA2_HUMAN BRCA2_HUMAN] Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:[https://omim.org/entry/114480 114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.<ref>PMID:16793542</ref> <ref>PMID:8640237</ref> <ref>PMID:9150152</ref> <ref>PMID:9654203</ref> <ref>PMID:9609997</ref> <ref>PMID:9971877</ref> <ref>PMID:10399947</ref> <ref>PMID:10978364</ref> <ref>PMID:11139248</ref> <ref>PMID:11241844</ref> <ref>PMID:12145750</ref> <ref>PMID:12373604</ref> <ref>PMID:12442274</ref> <ref>PMID:12442275</ref> <ref>PMID:11948477</ref> <ref>PMID:12938098</ref> <ref>PMID:15026808</ref> <ref>PMID:15172753</ref> <ref>PMID:14722926</ref> <ref>PMID:15365993</ref> Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:[https://omim.org/entry/613347 613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.<ref>PMID:9140390</ref> Defects in BRCA2 are a cause of susceptibility to familial breast-ovarian cancer type 2 (BROVCA2) [MIM:[https://omim.org/entry/612555 612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:[https://omim.org/entry/605724 605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.<ref>PMID:12065746</ref> <ref>PMID:14670928</ref> <ref>PMID:16825431</ref> Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:[https://omim.org/entry/613029 613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.<ref>PMID:15689453</ref> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/BRCA2_HUMAN BRCA2_HUMAN] Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication.<ref>PMID:15115758</ref> <ref>PMID:15199141</ref> <ref>PMID:15671039</ref> <ref>PMID:18317453</ref> <ref>PMID:20729859</ref> <ref>PMID:20729858</ref> <ref>PMID:20729832</ref> <ref>PMID:21084279</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Exchanges of protein sequence modules support leaps in function unavailable through point mutations during evolution. Here we study the role of the two RAD51-interacting modules within the eight binding BRC repeats of BRCA2. We created 64 chimeric repeats by shuffling these modules and measured their binding to RAD51. We found that certain shuffled module combinations were stronger binders than any of the module combinations in the natural repeats. Surprisingly, the contribution from the two modules was poorly correlated with affinities of natural repeats, with a weak BRC8 repeat containing the most effective N-terminal module. The binding of the strongest chimera, BRC8-2, to RAD51 was improved by -2.4 kCal/mol compared to the strongest natural repeat, BRC4. A crystal structure of RAD51:BRC8-2 complex shows an improved interface fit and an extended beta-hairpin in this repeat. BRC8-2 was shown to function in human cells, preventing the formation of nuclear RAD51 foci after ionizing radiation. | ||
| - | + | Improved RAD51 binders through motif shuffling based on the modularity of BRC repeats.,Lindenburg LH, Pantelejevs T, Gielen F, Zuazua-Villar P, Butz M, Rees E, Kaminski CF, Downs JA, Hyvonen M, Hollfelder F Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2017708118. doi: , 10.1073/pnas.2017708118. PMID:34772801<ref>PMID:34772801</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| + | <div class="pdbe-citations 6hqu" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Pyrococcus furiosus DSM 3638]] | ||
| + | [[Category: Hollfelder F]] | ||
| + | [[Category: Hyvonen M]] | ||
| + | [[Category: Lindenburg L]] | ||
| + | [[Category: Pantelejevs T]] | ||
Current revision
Humanised RadA mutant HumRadA22 in complex with a recombined BRC repeat 8-2
| |||||||||||
